Development and validation of a multiplex HPLC-MS/MS assay for the monitoring of JAK inhibitors in patient plasma
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Development and validation of a multiplex HPLC-MS/MS assay for the monitoring of JAK inhibitors in patient plasma
Authors
Keywords
-
Journal
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
Volume -, Issue -, Pages 123917
Publisher
Elsevier BV
Online
2023-10-29
DOI
10.1016/j.jchromb.2023.123917
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)
- (2023) Ohsang Kwon et al. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
- Upadacitinib Induction and Maintenance Therapy for Crohn’s Disease
- (2023) Edward V. Loftus et al. NEW ENGLAND JOURNAL OF MEDICINE
- A high-throughput UHPLC-MS/MS method for the determination of eight anti-tumor drugs in plasma
- (2023) Yao Liu et al. ANALYTICAL BIOCHEMISTRY
- Population Pharmacokinetics of Abrocitinib in Healthy Individuals and Patients with Psoriasis or Atopic Dermatitis
- (2022) Jessica Wojciechowski et al. CLINICAL PHARMACOKINETICS
- Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis
- (2022) Steven R. Ytterberg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Assessment of the Effects of Inhibition or Induction of CYP2C19 and CYP2C9 Enzymes, or Inhibition of OAT3, on the Pharmacokinetics of Abrocitinib and Its Metabolites in Healthy Individuals
- (2022) Xiaoxing Wang et al. EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS
- Evaluation of the inhibitory effect of quercetin on the pharmacokinetics of tucatinib in rats by a novel UPLC–MS/MS assay
- (2022) Ying Zhang et al. PHARMACEUTICAL BIOLOGY
- Upadacitinib Is Safe and Effective for Crohn’s Disease: Real-World Data from a Tertiary Center
- (2022) Cindy Traboulsi et al. DIGESTIVE DISEASES AND SCIENCES
- Efficacy of biological therapies and small molecules in induction and maintenance of remission in luminal Crohn’s disease: systematic review and network meta-analysis
- (2022) Brigida Barberio et al. GUT
- Rheumatoid arthritis: advances in treatment strategies
- (2022) Peeyush Prasad et al. MOLECULAR AND CELLULAR BIOCHEMISTRY
- Safety of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis
- (2022) Alexandre Sepriano et al. ANNALS OF THE RHEUMATIC DISEASES
- Upadacitinib Population Pharmacokinetics and Exposure-Response Relationships in Ulcerative Colitis Patients
- (2022) Ana Victoria Ponce-Bobadilla et al. CLINICAL PHARMACOKINETICS
- Frequency of Prescription Claims for Drugs that May Interact with Janus Kinase Inhibitors Among Patients with Rheumatoid Arthritis in the US
- (2021) Alison Walton et al. Rheumatology and Therapy
- In vivo Pharmacokinetic Drug-Drug Interaction Studies Between Fedratinib and Antifungal Agents Based on a Newly Developed and Validated UPLC/MS-MS Method
- (2021) Congrong Tang et al. Frontiers in Pharmacology
- Population Pharmacokinetics of Tofacitinib in Patients With Moderate to Severe Ulcerative Colitis
- (2021) Camille Vong et al. Clinical Pharmacology in Drug Development
- Development and clinical validation of a simple and fast UPLC-ESI-MS/MS method for simultaneous quantification of nine kinase inhibitors and two antiandrogen drugs in human plasma: Interest for their therapeutic drug monitoring
- (2021) Benoit Llopis et al. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
- Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis
- (2021) Thomas Bieber et al. NEW ENGLAND JOURNAL OF MEDICINE
- Upadacitinib Pharmacokinetics and Exposure‐Response Analyses of Efficacy and Safety in Psoriatic Arthritis Patients – Analyses of Phase 3 Clinical Trials
- (2021) Elena Muensterman et al. CTS-Clinical and Translational Science
- Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease
- (2021) Robert Zeiser et al. NEW ENGLAND JOURNAL OF MEDICINE
- Quantification of the janus kinase 1 inhibitor upadacitinib in human plasma by LC-MS/MS
- (2021) Jens Martens-Lobenhoffer et al. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
- Effects of Renal Impairment on the Pharmacokinetics of Abrocitinib and Its Metabolites
- (2021) Ellen Q. Wang et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Validation of enantioseparation and quantitation of an active metabolite of abrocitinib in human plasma
- (2021) Sakambari Tripathy et al. Bioanalysis
- Influence of Inflammation on Cytochromes P450 Activity in Adults: A Systematic Review of the Literature
- (2021) Camille Lenoir et al. Frontiers in Pharmacology
- The Steps to Therapeutic Drug Monitoring: A Structured Approach Illustrated With Imatinib
- (2020) Thierry Buclin et al. Frontiers in Pharmacology
- Critical Assessment of Pharmacokinetic Drug–Drug Interaction Potential of Tofacitinib, Baricitinib and Upadacitinib, the Three Approved Janus Kinase Inhibitors for Rheumatoid Arthritis Treatment
- (2020) Vijayabhaskar Veeravalli et al. DRUG SAFETY
- Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease
- (2020) Robert Zeiser et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pharmacokinetics, Safety, and Tolerability of Single‐ and Multiple‐Dose Once‐Daily Baricitinib in Healthy Chinese Subjects: A Randomized Placebo‐Controlled Study
- (2020) Xia Zhao et al. Clinical Pharmacology in Drug Development
- Population Pharmacokinetics of Upadacitinib Using the Immediate-Release and Extended-Release Formulations in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I–III Clinical Trials
- (2019) Ben Klünder et al. CLINICAL PHARMACOKINETICS
- Multiple administrations of fluconazole increase plasma exposure to ruxolitinib in healthy adult subjects
- (2019) Vassilios Aslanis et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Retrospective Claims Analysis Indirectly Comparing Medication Adherence and Persistence Between Intravenous Biologics and Oral Small-Molecule Therapies in Inflammatory Bowel Diseases
- (2019) Kellyn Moran et al. ADVANCES IN THERAPY
- Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia
- (2019) Ken Ogasawara et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Upadacitinib in Adults With Moderate-to-Severe Atopic Dermatitis: 16-Week Results From a Randomized, Placebo-Controlled Trial
- (2019) Emma Guttman-Yassky et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects With Rheumatoid Arthritis, Crohn's Disease, Ulcerative Colitis, or Atopic Dermatitis: Population Analyses of Phase 1 and 2 Clinical Trials
- (2019) Ahmed Nader et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Clinical Pharmacokinetics of Upadacitinib: Review of Data Relevant to the Rheumatoid Arthritis Indication
- (2019) Mohamed-Eslam F. Mohamed et al. CLINICAL PHARMACOKINETICS
- Effective quantification of 11 tyrosine kinase inhibitors and caffeine in human plasma by validated LC-MS/MS method with potent phospholipids clean-up procedure. Application to therapeutic drug monitoring
- (2019) Dora Koller et al. TALANTA
- Development and Validation of a Simultaneous Quantification Method of Ruxolitinib, Vismodegib, Olaparib, and Pazopanib in Human Plasma Using Liquid Chromatography Coupled With Tandem Mass Spectrometry
- (2018) Claire Pressiat et al. THERAPEUTIC DRUG MONITORING
- From method validation to result assessment: Established facts and pending questions
- (2018) Serge Rudaz et al. TRAC-TRENDS IN ANALYTICAL CHEMISTRY
- Development and validation of a rapid and sensitive UPLC-MS/MS assay for the quantification of tofacitinib in human plasma
- (2018) Kirtikumar D. Bharwad et al. BIOMEDICAL CHROMATOGRAPHY
- UPLC-MS/MS method for the simultaneous determination of imatinib, voriconazole and their metabolites concentrations in rat plasma
- (2018) Ren-ai Xu et al. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
- Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis
- (2017) Peter C. Taylor et al. NEW ENGLAND JOURNAL OF MEDICINE
- Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study
- (2017) Claire N Harrison et al. Lancet Haematology
- An LC-MS/MS method for rapid and sensitive high-throughput simultaneous determination of various protein kinase inhibitors in human plasma
- (2016) Ali S. Abdelhameed et al. BIOMEDICAL CHROMATOGRAPHY
- Biologic agents for IBD: practical insights
- (2015) Silvio Danese et al. Nature Reviews Gastroenterology & Hepatology
- Derivation of uncertainty functions from validation studies in biological fluids: Application to the analysis of caffeine and its major metabolites in human plasma samples
- (2014) Anne-Laure Gassner et al. JOURNAL OF CHROMATOGRAPHY A
- Population Pharmacokinetic Analysis of Orally-Administered Ruxolitinib (INCB018424 Phosphate) in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia Myelofibrosis (PET MF)
- (2013) Xuejun Chen et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Liver kidney microsomal type 1 antibodies reduce the CYP2D6 activity in patients with chronic hepatitis C virus infection
- (2012) F. Girardin et al. JOURNAL OF VIRAL HEPATITIS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More